04:36 PM EDT, 06/20/2025 (MT Newswires) -- InnoCan Pharma ( INNPF ) on Friday said the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" has been officially accepted for presentation at PAINWEEK 2025, in Las Vegas this September.

PAINWEEK brings together leading clinicians, researchers, and educators in the field of pain medicine, offering "a unique platform to showcase innovative research and best practices."

The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative, the company said.

Innocan is developing LPT-CBD, an injectable liposomal drug product designed for the sustained release of synthetic CBD.

"We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said CEO Iris Bincovich. "This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field."

Innocan closed trading up $0.03 to $0.23 on the Canadian Securities Exchange.